Tadashi Terui

Tadashi Terui

Auto-generated profile, based on publicly available information

Tadashi Terui

Nihon University School of Medicine, Itabashi, Japan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DFDaisuke Fujisawa
Daisuke Fujisawa
JKJun-Ichi Kashiwakura
Jun-Ichi Kashiwakura
HKHirohito Kita
Hirohito Kita
YKYusuke Kikukawa
Yusuke Kikukawa
YFYasushi Fujitani
Yasushi Fujitani
Yoshimichi OkayamaYoshimichi Okayama
Yoshimichi Okayama

19 September 2018 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
HFHideki Fujita
Hideki Fujita
TTTadashi Terui
Tadashi Terui
KHKoremasa Hayama
Koremasa Hayama
MAMasashi Akiyama
Masashi Akiyama
SIShigaku Ikeda
Shigaku Ikeda
TPThe Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis
The Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis

1 January 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
BSBruce Strober
Bruce Strober
CRCaitriona Ryan
Caitriona Ryan
PKPeter van de Kerkhof
Peter van de Kerkhof
JWJoelle van der Walt
Joelle van der Walt
AKAlexa B. Kimball
Alexa B. Kimball
MZMin Zheng
Min Zheng
Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis. To develop a consensus statement on the classification of psoriasis severity. A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity. After completion of the exercise, 7 severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy. This effort might have suffered from a lack of representation by all relevant stakeholders, including patients. The consensus statement describes 2 categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.

1 April 2020 in Journal of Dermatological Science
Verified
Journal Article
Closed access
MMMasamoto Murakami
Masamoto Murakami
TTTadashi Terui
Tadashi Terui

7 February 2018 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
TTTadashi Terui
Tadashi Terui
SKSatomi Kobayashi
Satomi Kobayashi
YOYukari Okubo
Yukari Okubo
MMMasamoto Murakami
Masamoto Murakami
KHKeiichiro Hirose
Keiichiro Hirose
HKHiroshi Kubo
Hiroshi Kubo
Palmoplantar pustulosis (PPP), a chronic, relapsing inflammatory skin disease, is characterized by the presence of multiple sterile pustules subsequent to the formation of vesicles along with erythematous scaling, particularly confined to the palms and soles.1-5 It is a severe, recalcitrant disorder with a greater adverse impact on quality of life than other forms of inflammatory skin lesions located elsewhere on the body.3,6 Tobacco smoking, focal infections (eg, tonsillitis), and seasonal conditions have been identified as common risk factors for triggering or worsening PPP, and middle-aged women are thought to be at a higher risk.2,7-10 Data from a national health insurance claim database estimated the prevalence of PPP in Japan to be 0.12%, generally higher than in the Western population.11

1 October 2019 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
TTTadashi Terui
Tadashi Terui
SKSatomi Kobayashi
Satomi Kobayashi
YOYukari Okubo
Yukari Okubo
MMMasamoto Murakami
Masamoto Murakami
RZRichuan Zheng
Richuan Zheng
TKTakayuki Kimura
Takayuki Kimura
Palmoplantar pustulosis (PPP) is a chronic, relapsing, inflammatory skin disease characterized by the presence of multiple sterile pustules subsequent to formation of vesicles along with erythematous scaling and is confined to the palms and soles.1 Daily activities are impaired in patients with PPP compared with those with plaque psoriasis because PPP causes greater physical disability by restricting use of the palms and soles.2 Although the pathogenesis of PPP is not fully understood, multiple factors that aggravate PPP are recognized; these include exaggerated production of proinflammatory cytokines3 and stimulation induced by numerous triggers, such as smoking and infectious agents.4,5 Palmoplantar pustulosis occurs more frequently in women6,7 and is associated with smoking.8 The prevalence of PPP in Japan is approximately 0.12%, which is comparatively higher than that in the Western population.7